Pharma BD Deal Intelligence
AstraZeneca's Alexion exercised its option to acquire all remaining equity in Caelum Biosciences (Oct 2021) for $150M upfront plus up to $350M in regulatory/commercial milestones (~$500M total), building on Alexion's January 2019 stake-plus-option. The lead asset, CAEL-101 (now anselamimab), is a potentially first-in-class fibril-reactive monoclonal antibody designed to clear amyloid deposits in AL amyloidosis. The thesis hinged on the pivotal CARES Phase III programme (CARES-1/-2, >400 patients in Mayo Stage IIIa/IIIb cardiac AL). CARES MISSED its primary endpoint in the overall population (March 2025). Updated full results presented at ASCO 2026 (29 May 2026) and published in JCO showed a prespecified kappa light-chain subgroup (n=72) with nominally significant, clinically meaningful benefit: all-cause mortality reduced 62% (HR 0.38) and cardiovascular hospitalizations reduced 71% (IRR 0.29), with mortality reductions of 75% in Mayo IIIa and 48% in Mayo IIIb. AstraZeneca has repositioned the program to the kappa subset and is pursuing regulatory submissions for kappa AL amyloidosis in the EU and Japan; a US FDA submission is not currently listed in its pipeline. The broad-population failure puts most of the $350M contingent milestones at risk, while the narrowed kappa path preserves partial first-in-class optionality.